Insights into antibiotic–carrier interactions in the silk-fibroin-based nanoparticles and considerations on the formulation process greenness are limited. Hence, this work developed and characterized ...

Discover Protalix BioTherapeutics' Q4 2024 earnings insights, including record revenues, pipeline advancements, and future growth prospects.

Q4 2024 Earnings Call Transcript March 17, 2025 Protalix BioTherapeutics, Inc. beats earnings expectations. Reported EPS is $0.09, expectations were $0.07. Operator: Good morning, ladies and gentlemen ...

The convergence of AI and drug delivery is opening new frontiers in precision medicine. AI-powered predictive modeling is ...

Department of Chemical Engineering and Materials Science, Wayne State University, 5050 Anthony Wayne Drive, Detroit, Michigan 48202, United States ...

I would like to start with PRX-115, which is our recombinant PEGylated uricase candidate in development for the treatment of uncontrolled gout. We produce PRX-115 through our ProCellEx platform.

PLX READ THE FULL PLX RESEARCH REPORT 2024 Financial and Operational Review Protalix Biotherapeutics, Inc. (NYSE:PLX) announced 2024 financial and operational results in a March 17th, 2024 press ...

以列线图的形式呈现该预测模型，用于定量预测慢乙肝患者接受PEG IFNα治疗48周后的HBsAg清除率。通过基线HBsAg水平、性别和肝硬化状态，可以初步简易评估患者接受PEG ...

After hours: March 19 at 5:25:19 PM EDT Loading Chart for RLYB ...

Incorporating systems thinking into drug value assessment promises more realistic evaluations of the impact of new therapies, ...

and is also exploring use of the drug in combination with current therapies including pegylated interferon (PegIFN) and its experimental immunotherapies. GSK licensed the drug from longstanding ...